Prepared by the UK BTS Joint Professional Advisory Committee’s (JPAC) HTLV Working Group
Subsequent to the SaBTO meeting of 1st September 2015, the cost-effectiveness analysis reported in Section 10 of the “Options for Human T-Lymphotropic Virus (HTLV) screening within the UK Blood Services” paper (item 5) has been updated to incorporate members’ requests:
In addition to these requested updates, better estimates have been implemented for the number of infected and tested issues, and a minor error in the QALY calculation corrected. While this has impacted some of the more extreme values reported, the relative relationships and conclusions of the original report remain the same.